Managing adverse effects of cutaneous T-cell lymphoma treatment with supportive care measures

Abstract

. Over the last 15 years, the number of therapies for CTCL has grown rapidly and continues to do so as new medications are enter-ing clinical trials and seeking US FDA approval. Adverse events (AEs) related to a new therapy sometimes become the treatment-limiting factor. Fortunately, AEs for many medications can be suc-cessfully managed, allowing for contin-ued use and benefit from therapy. Here, we discuss the management of common AEs of several topical and systemic medi -cations frequently used in the treatment of CTCL.